New anti-rebate legislation in South Korea

Applied Health Economics and Health Policy

Volumn 11, Issue 4, 2013, Pages 311-318

  Yu, Su Yeon ^a   Yang, Bong Min ^a   Kim, Jin Hyun ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CONSUMER ADVOCACY; DRUG COST; DRUG DISTRIBUTION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC EVALUATION; GROSS NATIONAL PRODUCT; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; PHARMACIST; PHARMACY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; REIMBURSEMENT; REVIEW; SOUTH KOREA;

FINANCING, GOVERNMENT; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; REPUBLIC OF KOREA;

EID: 84880864268     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0029-x     Document Type: Review

References (30)

1. Korea Fair Trade Commission. Corrective Measures against improper concerted acts by 10 pharmaceutical companies. [online]. [InlineMediaObject not available: see fulltext.]. Accessed 1 March 2013.
2. US International Trade Commission. US-Korea Free Trade Agreement: Potential Economy-wide and Selected Sectoral Effects, Chapter 3. Sector-specific assessment, 2007. p. 65-6.
3. The Ministry of Health and Welfare in Korea. Reducing price of a drug involved in rebates, [online]. [InlineMediaObject not available: see fulltext.]. Accessed 12 July 2012.
4. SBS Newspapers, Continuous suicide of salesmen, Why? [online]. http://news.sbs.co.kr/section-news/news-read.jsp?news-id=N1000688080. Accessed 1 March 2013.
5. IMS Health. Pharmerging shake-up: new imperatives in a redefined world. [online]. http://libproxy.catholic.ac.kr/be022ed/-Lib-Proxy-Url/search.proquest. com/docview/1034409304/fulltextPDF/13CBE5FB1203B022CF2/9?accountid=10373. Accessed 1 March 2013.
6. Hong SW, The current status and regulations on MRCT in Korea. Asia-Pacific Economic Cooperation. [online]. http://www.apec-ahc.org/files/ tp201002/Session4-SoonWookHong.pdf. Accessed 1 March 2013.
7. National Health Insurance Corporation. Statistical Yearbook. 2010.
8. Yang B, Bae E, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff. 2008;27(1):179-87. (Pubitemid 351198603)
9. Lee H, Kim J. Delisting policy reform in South Korea: failed or policy change? Value Health. 2011;15:204-12.
10. OECD, Health Data. 2011.
11. Lim D, Choi H, Joung M, et al. The Study on Pharmaceutical Industry Anaylsis, Korea Health Industry Development Institute. 2010.
12. Korea Pharmaceutical Statistics. Korea Pharmaceutical Manufacturers Association. 2010.
13. Lee G, Seo K, Lim D, et al. Fact and analysis of the research and development in health industry. Korea Health Industry Development Institute. 2009.
14. Joung M, Lee B, Joung Y, et al. The study on pharmaceutical industry. Korea Health Industry Development Institute. 2008.
15. The Ministry of Health and Welfare in Korea. New Policy of Drug Price. [online]. [InlineMediaObject not available: see fulltext.] Accessed 1 March 2013.
16. Taylor D, Mrazek M, Mossialos E. Regulating pharmaceuticals distribution and retail pharmacy in Europe. In: Mossialos E, Mrazek M, Walley T, editors. Regulating pharmaceuticals in Europe. Maidenhead: Open University Press; 2004. p. 196-212.
17. Joung Y, Lee B, Joung M, et al. A study on the development of pharmaceutical wholesalers industry. Korea Health Industry Development Institute. 2010.
18. Daily Pharm. Heavy Penalty imposed on 9 drug companies for illegal rebates. [online]. http://www.dreamdrug.com/Users/News/NewsView.html?ID=141670. Accessed 1 March 2013.
19. The Ministry of Health and Welfare in Korea. The direction for transparency and enhancement of drug circulation. [online]. http://www.kpanews. co.kr/bbs/data/kpanews-l.asp?show-idx=8301&table=bbs-data&category= 1&page=6&search=&keyword=. Accessed 1 March 2013.
20. Korean Food and Drug Administration. The Pharmaceutical Affairs Acts. 2010.
21. Dailymedi. Doctors keep boycotting products from 5 pharmaceutical companies who are in support of the DPS legislation. [online]. http://66.232.143.22/news/view.html?skey=%B0%A3%BE%CF&page=5§ion= 1&category=4&no=457538. Accessed 12 July 2012.
22. The Board of Audit and Inspection of Korea. Audit on Management of NHI drugs. 2012.
23. The Study on Pharmaceutical Industry Anaylsis, 2012, Korea Health Industry Developement Institute. [online]. http://www.bai.go.kr/. Accessed 1 March 2013.
24. Korea Fair Trade Commission. Exposed illegal rebate by pharmaceutical companies. [online]. http://www.ftc.go.kr/news/ftc/reportList.jsp. Accessed 1 March 2013.
25. Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343-9.
26. Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527-38.
27. McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73-85.
28. Roehr B. Drug companies will have to report all payments to US doctors from March 2014. BMJ 2013;346. doi: 10.1136/bmj.f826.
29. Godman B, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65-83.
30. Brkicic LS, Godman B, Voncina L, et al. Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):373-84.